



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 9.08.2024

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai – 400070  
Dear Sir,

Sub: Submission of unaudited financial results of the Company for the quarter ended 30<sup>th</sup> June, 2024 along with the Limited review report - Reg.

Ref: Disclosure under Regulation 30 & 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Friday, 9<sup>th</sup> August, 2024 had inter-alia considered transacted and approved the following items of business:

1. Approved the unaudited financial results along with Segment Results for the quarter ended 30<sup>th</sup> June, 2024 with limited review report issued by the statutory auditors.
2. The board recommended the reappointment of Sri. P.C. Sai Babu (DIN: 10275666) as Non-Executive Non Independent director of the company, who retires by rotation and eligible for reappointment subject to the approval of shareholders at the ensuing Annual General Meeting.
3. Recommendation for the reappointment of Sri. G. Mohan Rao (DIN:08535558), as an independent director for a period of five consecutive years with effect from 27.9.2024, subject to the approval of shareholders at the ensuing AGM of the company.
4. Approved the leasing of both the factories of the company, subject to the approval of shareholders at the ensuing Annual General Meeting.
5. Approved the alteration of remuneration clause for Sri. Tunuguntla Raja Sekhar, Executive Director of the company who was appointed by the board at its meeting held on 25.5.2024 as Whole Time Director (KMP) in the capacity and designation of Executive Director of the Company within the overall quantum of remuneration approved earlier on 25.5.2024.

LEKHA SAI  
SURAPAN  
ENI

Digitally signed by LEKHA SAI  
SURAPANENI  
DN: c=N, o=Personal,  
postalCode=500033,  
st=Telangana,  
serialNumber=A1D0E6EA34428E6  
46596A596CB8873ED72FE0DB48  
3383EAD1814D40202929AB,  
cn=LEKHA SAI SURAPANENI  
Date: 2024.08.09 18:42:07 +05'30'



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

6. Approved the Directors report along with the annexures'.

7. Approved the Notice of the 30<sup>th</sup> Annual General Meeting and the AGM will be held on Monday, the 9<sup>th</sup> day of September, 2024 at 4.00 P.M. through Video Conferencing (VC) / Other Audio Visual Means ('OAVM') and also approved the Annual Report for the year 2023 - 2024.

8. The Register of Members and Share Transfer Registers will be closed from Tuesday, 3<sup>rd</sup> September, 2024 to Monday, 9<sup>th</sup> September, 2024 (both the days inclusive) and the record date (cut-off date) will be 2<sup>nd</sup> September, 2024.

9. The board has appointed Mr. D. Venkata Ratnam, Chartered Accountant, partner of M/s. Suresh and Babu, Chartered Accountants as Scrutinizer for the 30<sup>th</sup> AGM to be held on 9.9.2024.

Accordingly, please find enclosed herewith the following:

1. Un-Audited financial Results along with segment results and Limited Review Report for the quarter ended 30<sup>th</sup> June, 2024.

2. Form-A relating to Sri. P.C. Sai Babu, proposed to be reappointed as the Director of the Company subject to the approval of members at the ensuing 30<sup>th</sup> Annual General Meeting.

Further we wish to inform that following regulations are not applicable to our company:

a. The company do not have any Non-convertible Instruments (Debt), as such Reg. 52(4) & 52(6) SEBI (LODR) Regulations, 2015 is not applicable to the company.

b. Reg. 54(2)/(3) SEBI (LODR) Regulations, 2015 – No security cover created as we do not have any secured listed non - convertible debt Instruments.

Kindly take the above on your records.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

LEKHA SAI  
SURAPANENI  
NI

Digitally signed by LEKHA SAI  
SURAPANENI  
DN: cn=IL, ou=Personal,  
postalCode=500033, st=Telangana,  
serialNumber=A1DDE6EA34428E646  
596A596CB8873ED72FE0DB483383  
EFA01B944D820B298AB, cn=LEKHA  
SAI SURAPANENI  
Date: 2024.08.09 18:42:35 +05'30'

(Lekha Sai Surapaneni)  
Company Secretary

The meeting Commenced at 4:00 PM  
The Meeting Concluded at 6:30 PM



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

## Form A

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Reappointment of Sri. P.C. Sai Babu (DIN: 10275666), as Non-Executive Non Independent director of the company of the Company:

a.	Reason for change viz. <del>appointment, reappointment resignation, removal, death or otherwise</del>	Reappointment of Mr. China Sai Babu Puppala, as Non-Executive Non Independent Director of the Company liable for retirement by rotation, subject to the approval of members of the Company at the ensuing 30 <sup>th</sup> Annual General Meeting ('AGM").
b.	Date of appointment/ <del>reappointment/cessation (as applicable) &amp; term of appointment/reappointment;</del>	Appointed by members at the 29 <sup>th</sup> AGM held on 27 <sup>th</sup> September, 2023, liable to retire by rotation.
c.	Brief profile (in case of appointment);	Mr. P.C. Sai Babu, B.Com., FCA., aged about 71 years, is a practicing Chartered Accountant with about 37 years of experience. Earlier i.e., from 1978 to 1982 he had worked in AP Civil Supplies Corporation Limited, and from 1982 to 1985 he had worked in AP Construction Corporation Limited and thus he is having varied experience.
d.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
e.	Disclosure pursuant to BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018	Mr. P.C. Sai Babu, is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority.

LEKHA SAI  
SURAPAN  
ENI

Digitally signed by LEKHA SAI  
SURAPANENI  
DN: cn=, o=Personal,  
postalCode=500033,  
st=Telangana,  
serialNumber=A1DDE6EA3442BE6  
465964A596CBB873ED72FE0DB4B  
3383EFAD1BF4D82DB298AB,  
cn=LEKHA SAI SURAPANENI  
Date: 2024.08.09 18:42:57 +05'30'

**SIGACHI LABORATORIES LIMITED**

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230 / 23204273

Website: www.sllab.com, Email: sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For The Quarter Ended 30th June, 2024

(Rs.in lakhs)

Sl.No.	Particulars	Quarter ended			Year ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	<b>Income</b>				
1	Revenue from operations	140.24	76.65	100.96	374.14
2	Other income	1.60	15.74	9.62	61.86
3	<b>Total Income (1+2)</b>	<b>141.84</b>	<b>92.39</b>	<b>110.58</b>	<b>436.00</b>
4	<b>Expenses</b>				
	a) Cost of materials consumed	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-
	c) Impairment on Advances	-	-	-	75.00
	d) Fair Value Loss	-	-	-	-
	e) Employee benefits expense	10.09	11.25	9.56	39.37
	f) Finance costs	-	-	-	-
	g) Depreciation and amortization expense	5.30	6.05	5.00	22.51
	h) Other expenses	4.30	6.33	4.19	17.53
	<b>Total Expenses</b>	<b>19.69</b>	<b>23.63</b>	<b>18.75</b>	<b>154.41</b>
5	<b>Profit/(Loss) before exceptional items and tax (3-4)</b>	<b>122.15</b>	<b>68.76</b>	<b>91.83</b>	<b>281.59</b>
6	Exceptional Items	-	-	-	-
7	<b>Profit/(Loss) before tax (5-6)</b>	<b>122.15</b>	<b>68.76</b>	<b>91.83</b>	<b>281.59</b>
8	<b>Tax expense</b>				
	(a) Current tax	4.58	13.41	6.45	40.95
	(b) Deferred tax	(8.45)	23.98	9.97	43.18
	<b>Total Tax Expense</b>	<b>(3.87)</b>	<b>37.39</b>	<b>16.42</b>	<b>84.13</b>
9	<b>Profit/(Loss) for the Period (7-8)</b>	<b>126.02</b>	<b>31.37</b>	<b>75.41</b>	<b>197.46</b>
10	<b>Other Comprehensive income (OCI)</b>				
	(a) Items that will not be reclassified to profit or loss	274.61	18.09	141.82	367.56
	(b) Remeasurement gains/(losses) on defined benefit plans	-	0.20	-	0.20
	Tax on Items that will not be reclassified to profit or loss	(28.56)	1.73	(14.75)	(38.28)
	(c) Items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive income</b>	<b>246.05</b>	<b>20.02</b>	<b>127.07</b>	<b>329.48</b>
	<b>Total Comprehensive income (9+10)</b>	<b>372.07</b>	<b>51.39</b>	<b>202.48</b>	<b>526.94</b>
11	<b>Paid-up Equity Share Capital (Face Value Rs.10/- per share)</b>	<b>675.31</b>	<b>675.31</b>	<b>675.31</b>	<b>675.31</b>
12	<b>Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,869.84</b>
13	<b>Earnings per equity share (of Rs 10/- each) (not annualized (Rs.))</b>				
	(1) Basic	1.87	0.46	1.12	2.92
	(2) Diluted	1.87	0.46	1.12	2.92

**RAJASEKHA**  
R  
**TUNUGUNT**  
LA

Digitally signed by RAJASEKHAR  
TUNUGUNTLA  
DN: c=IN, o=Personal,  
postalCode=560067,  
st=Karnataka,  
serialNumber=68020441AFA9D26  
223CZDF4DDF50C34C9458E946  
FEB5F41512C31E9A5D5A805,  
cn=RAJASEKHAR TUNUGUNTLA  
Date: 2024.08.09 18:43:25 +05'30'

Segment wise Revenue, Results and Capital Employed for the Quarter Ended 30th June, 2024

(Rs.in lakhs)

Sl No	Particulars	Quarter ended			Year ended
		30.06.2024	31.03.2024	30.06.2023	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment Revenue				
	a) Bulk Drugs and Intermediates (Lease Rents)	23.00	46.00	22.00	134.50
	b) Investments	118.84	46.39	88.58	301.50
	Total	141.84	92.39	110.58	436.00
	Less: Inter Segment Revenue	-	-	-	-
	Net Sales/Income from Operations	141.84	92.39	110.58	436.00
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment				
	a) Bulk Drugs and Intermediates (Lease Rents)	17.32	38.84	16.55	110.07
	b) Investments	118.84	46.39	88.58	301.50
	Total	136.16	85.23	105.13	411.57
	Less: (i) Finance Costs	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	14.01	16.47	13.30	129.98
	(iii) Un-allocable income	-	-	-	-
	Total Profit Before Tax	122.15	68.76	91.83	281.59
3	Capital Employed				
	(Segment Assets – Segment Liabilities)				
	a) Bulk Drugs and Intermediates	810.01	818.54	899.91	818.54
	b) Investments	3,162.96	2,782.36	2,376.53	2,782.36
	Total	3,972.97	3,600.90	3,276.44	3,600.90

Notes :

- The above statement of unaudited financial results of the Company, which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on August 9, 2024. The Statutory Auditors have carried out a limited review on the unaudited financial results and issued an unmodified report thereon.
- No material adjustments were made in the results for the current quarter/year which pertain to earlier periods/year. Hence, the figures have not been regrouped or reclassified.
- The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which were subject to limited review.
- These Financial Results are available on the Stock Exchange website (www.mseil.in) and also on the company's website at (www.slilab.com).

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad  
Date : 09.08.2024

(T.R.Sekhar)  
Executive Director  
DIN:02943146

RAJASEKH  
AR  
TUNUGUN  
TLA

Digitally signed by RAJASEKHAR  
TUNUGUNTLA  
DN: c=IN, o=Personal,  
postalCode=560067,  
st=Karnataka,  
serialNumber=680204411AFA9D  
262233C7DF4DDF50C34C9458E  
946F8B5F41512C31E9A5D5A805  
, cn=RAJASEKHAR TUNUGUNTLA  
Date: 2024.08.09 18:43:51  
+05'30'



**Limited Review Report on Unaudited Financial Results of M/s Sigachi Laboratories Limited**

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s SIGACHI LABORATORIES LIMITED pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF  
Sigachi Laboratories Limited**

We have reviewed the accompanying unaudited financial results of **M/s Sigachi Laboratories Limited**, for the quarter ended June 30. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Sigachi Laboratories Limited** as at June 30, 2024.

For NSVR & Associates LLP  
Chartered Accountants  
FRN: 008801S/S200060

*V. Gangadhara Rao N*

V Gangadhara Rao N  
Partner  
M. No.219486  
UDIN: 24219486BKFBBC3431



Place: Hyderabad  
Date: 09-08-2024.



<b>General information about company</b>	
Scrip code	000000
NSE Symbol	
MSEI Symbol	SIGACHI
ISIN*	INE368H01018
Name of company	SIGACHI LABORATORIES LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	09-08-2024
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	01-08-2024
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	09-08-2024 04:00
End date and time of board meeting	09-08-2024 06:30
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	140.237	140.237
	Other income	1.602	1.602
	<b>Total income</b>	<b>141.839</b>	<b>141.839</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	10.09	10.09
(e)	Finance costs	0	0
(f)	Depreciation, depletion and amortisation expense	5.302	5.302
<b>(f)</b>	<b>Other Expenses</b>		
1	Vehicle Maintenance	0.865	0.865
2	Miscellaneous Expenses	0.633	0.633
3	Listing Fee	0.55	0.55
4	Custody Fee	0.45	0.45
5	Rent	0.42	0.42
6	Conveyance Expenses	0.369	0.369
7	Insurance	0.259	0.259
8	Office Maintenance	0.171	0.171
9	Share Transfer and Depository Fee	0.145	0.145
10	Other Expenses	0.436	0.436
	<b>Total other expenses</b>	<b>4.298</b>	<b>4.298</b>
	<b>Total expenses</b>	<b>19.69</b>	<b>19.69</b>



<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 months ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>3</b>	<b>Total profit before exceptional items and tax</b>	122.149	122.149
4	Exceptional items	0	0
<b>5</b>	<b>Total profit before tax</b>	122.149	122.149
<b>7</b>	<b>Tax expense</b>		
8	Current tax	4.578	4.578
9	Deferred tax	-8.446	-8.446
<b>10</b>	<b>Total tax expenses</b>	-3.868	-3.868
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>14</b>	<b>Net Profit Loss for the period from continuing operations</b>	126.017	126.017
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
<b>17</b>	<b>Net profit (loss) from discontinued operation after tax</b>	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>21</b>	<b>Total profit (loss) for period</b>	126.017	126.017

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Other comprehensive income [Abstract]</b>			
<b>1</b>	<b>Amount of items that will not be reclassified to profit and loss</b>		
1	Items that will not be reclassified to profit or loss	274.608	274.608
	<b>Total Amount of items that will not be reclassified to profit and loss</b>	274.608	274.608
2	<b>Income tax relating to items that will not be reclassified to profit or loss</b>	28.559	28.559
<b>3</b>	<b>Amount of items that will be reclassified to profit and loss</b>		
	<b>Total Amount of items that will be reclassified to profit and loss</b>		
4	<b>Income tax relating to items that will be reclassified to profit or loss</b>	0	0
<b>5</b>	<b>Total Other comprehensive income</b>	246.049	246.049

<b>Financial Results – Ind-AS</b>			
<b>Particulars</b>		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2024	01-04-2024
B	Date of end of reporting period	30-06-2024	30-06-2024
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>23</b>	<b>Total Comprehensive Income for the period</b>	372.066	372.066
<b>24</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
<b>25</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
<b>26</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	675.31	675.31
	Face value of equity share capital	10	10
<b>27</b>	<b>Details of debt securities</b>		
28	Reserves excluding revaluation reserve		
<b>29</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	1.866	1.866
	Diluted earnings (loss) per share from continuing operations	1.866	1.866
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>ii</b>	<b>Earnings per equity share</b>		
	<b>Basic earnings (loss) per share from continuing and discontinued operations</b>	1.866	1.866
	<b>Diluted earnings (loss) per share from continuing and discontinued operations</b>	1.866	1.866
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
<b>33</b>	<b>Disclosure of notes on financial results</b>	Textual Information(1)	

<b>Text Block</b>	
Textual Information(1)	<p>1.The above statement of unaudited financial results of the Company, which have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on August 9, 2024. The Statutory Auditors have carried out a limited review on the unaudited financial results and issued an unmodified report thereon.</p> <p>2.No material adjustments were made in the results for the current quarter/year which pertain to earlier periods/year. Hence, the figures have not been regrouped or reclassified.</p> <p>3.The figures for the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which were subject to limited review.</p> <p>4.These Financial Results are available on the Stock Exchange website (<a href="http://www.msei.in">www.msei.in</a>) and also on the company's website at (<a href="http://www.slllab.com">www.slllab.com</a>).</p>

<b>Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results</b>			
<b>Particulars</b>		<b>3 months/ 6 month ended (dd-mm-yyyy)</b>	<b>Year to date figures for current period ended (dd-mm-yyyy)</b>
Date of start of reporting period		01-04-2024	01-04-2024
Date of end of reporting period		30-06-2024	30-06-2024
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
<b>1</b>	<b>Segment Revenue (Income)</b>		
	<b>(net sale/income from each segment should be disclosed)</b>		
1	Bulk Drugs and Intermediates (Lease Rents)	23	23
2	Investments	118.839	118.839
	<b>Total Segment Revenue</b>	<b>141.839</b>	<b>141.839</b>
	<b>Less: Inter segment revenue</b>	<b>0</b>	<b>0</b>
	<b>Revenue from operations</b>	<b>141.839</b>	<b>141.839</b>
<b>2</b>	<b>Segment Result</b>		
	<b>Profit (+) / Loss (-) before tax and interest from each segment</b>		
1	Bulk Drugs and Intermediates (Lease Rents)	17.323	17.323
2	Investments	118.839	118.839
	<b>Total Profit before tax</b>	<b>136.162</b>	<b>136.162</b>
	<b>i. Finance cost</b>	<b>0</b>	<b>0</b>
	<b>ii. Other Unallocable Expenditure net off Unallocable income</b>	<b>14.013</b>	<b>14.013</b>
	<b>Profit before tax</b>	<b>122.149</b>	<b>122.149</b>
<b>3</b>	<b>(Segment Asset - Segment Liabilities)</b>		
	<b>Segment Asset</b>		
1	Bulk Drugs and Intermediates (Lease Rents)	963.968	963.968
2	Investments	3162.962	3162.962
	<b>Total Segment Asset</b>	<b>4126.93</b>	<b>4126.93</b>
	<b>Un-allocable Assets</b>	<b>0</b>	<b>0</b>
	<b>Net Segment Asset</b>	<b>4126.93</b>	<b>4126.93</b>
<b>4</b>	<b>Segment Liabilities</b>		
	<b>Segment Liabilities</b>		
1	Bulk Drugs and Intermediates (Lease Rents)	153.962	153.962
2	Investments	0	0
	<b>Total Segment Liabilities</b>	<b>153.962</b>	<b>153.962</b>
	<b>Un-allocable Liabilities</b>		
	<b>Net Segment Liabilities</b>	<b>153.962</b>	<b>153.962</b>
	<b>Disclosure of notes on segments</b>		

